LRP4 Inhibitors
LRP4 inhibitors constitute a diverse set of chemicals with the ability to modulate the activity of the transmembrane receptor LRP4. These inhibitors exert their effects through intricate interference with specific signaling pathways, influencing the downstream events associated with LRP4 function. One notable indirect inhibitor, LDN-193189, disrupts LRP4 indirectly through the BMP (Bone Morphogenetic Protein) signaling pathway. LDN-193189 inhibits BMP type I receptors, attenuating BMP signaling, which is known to interact with LRP4 in neuromuscular junction formation. By interfering with BMP-mediated events involving LRP4, LDN-193189 presents an avenue for modulating LRP4 activity. Niclosamide, another LRP4 inhibitor, exerts its effects through the Wnt/β-catenin signaling pathway. By disrupting the function of Dishevelled (Dvl), a key component of the Wnt pathway, Niclosamide inhibits Wnt signaling. Given LRP4's involvement in Wnt signaling in specific contexts, Niclosamide offers a strategy for indirectly inhibiting LRP4 by interfering with the Wnt pathway.
FH535, an LRP4 inhibitor, disrupts LRP4 indirectly through the Wnt/β-catenin signaling pathway. FH535 inhibits the interaction between β-catenin and TCF/LEF transcription factors, attenuating Wnt signaling. This interference with Wnt/β-catenin signaling offers FH535 as a candidate for modulating LRP4 activity indirectly. SB431542, another LRP4 inhibitor, influences LRP4 indirectly through the TGF-β signaling pathway. By inhibiting the activin receptor-like kinase (ALK) receptors, SB431542 attenuates TGF-β signaling, which interacts with LRP4. This inhibition disrupts TGF-β-mediated events involving LRP4, providing SB431542 as a modulator of LRP4 activity. PRI-724, another LRP4 inhibitor, influences LRP4 indirectly through the Wnt/β-catenin signaling pathway. By inhibiting the interaction between β-catenin and CBP, PRI-724 attenuates Wnt signaling. This interference with Wnt/β-catenin signaling presents PRI-724 as a modulator of LRP4 activity through an indirect mechanism.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
4-(6-(4-(Piperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)quinoline | 1062368-24-4 | sc-476297 | 5 mg | $240.00 | ||
Also called LDN-193189, this compound serves as an indirect inhibitor of LRP4 through the BMP (Bone Morphogenetic Protein) signaling pathway. By inhibiting BMP type I receptors, LDN-193189 attenuates BMP signaling, leading to reduced phosphorylation of downstream effectors. | ||||||
Niclosamide | 50-65-7 | sc-250564 sc-250564A sc-250564B sc-250564C sc-250564D sc-250564E | 100 mg 1 g 10 g 100 g 1 kg 5 kg | $37.00 $77.00 $184.00 $510.00 $1224.00 $5814.00 | 8 | |
Niclosamide acts as an indirect inhibitor of LRP4 through the Wnt/β-catenin signaling pathway. By disrupting the function of Dishevelled (Dvl), a key component of the Wnt pathway, Niclosamide inhibits Wnt signaling. Since LRP4 is implicated in Wnt signaling in certain contexts, Niclosamide can potentially inhibit LRP4 activity by interfering with the Wnt/β-catenin pathway. | ||||||
A 83-01 | 909910-43-6 | sc-203791 sc-203791A | 10 mg 50 mg | $198.00 $650.00 | 16 | |
A83-01 serves as an indirect inhibitor of LRP4 through the TGF-β (Transforming Growth Factor-β) signaling pathway. By inhibiting the TGF-β type I receptor, A83-01 attenuates TGF-β signaling, which is known to interact with LRP4 in neuromuscular junction regulation. | ||||||
LDN-214117 | 1627503-67-6 | sc-507451 | 5 mg | $165.00 | ||
LDN-214117 acts as an indirect inhibitor of LRP4 through the Wnt/β-catenin signaling pathway. By inhibiting Porcupine, an enzyme critical for Wnt secretion, LDN-214117 disrupts Wnt signaling. As LRP4 is implicated in Wnt pathway regulation, LDN-214117 can potentially inhibit LRP4 activity by interfering with Wnt signaling. | ||||||
β-Catenin/Tcf Inhibitor, FH535 | 108409-83-2 | sc-221398 sc-221398A | 10 mg 50 mg | $178.00 $367.00 | 7 | |
FH535 serves as an indirect inhibitor of LRP4 through the Wnt/β-catenin signaling pathway. By inhibiting the interaction between β-catenin and TCF (T-cell factor)/LEF (lymphoid enhancer factor) transcription factors, FH535 attenuates Wnt signaling. Since LRP4 is involved in Wnt pathway regulation, FH535 can potentially inhibit LRP4 activity by interfering with Wnt/β-catenin signaling. | ||||||
XAV939 | 284028-89-3 | sc-296704 sc-296704A sc-296704B | 1 mg 5 mg 50 mg | $35.00 $115.00 $515.00 | 26 | |
XAV939 acts as an indirect inhibitor of LRP4 through the Wnt/β-catenin signaling pathway. By inhibiting tankyrase, XAV939 stabilizes Axin, leading to increased degradation of β-catenin. Since LRP4 is implicated in Wnt pathway regulation, XAV939 can potentially inhibit LRP4 activity by promoting the degradation of β-catenin and attenuating Wnt signaling. | ||||||
ALK5 Inhibitor II | 446859-33-2 | sc-221234 sc-221234A sc-221234B sc-221234C sc-221234D sc-221234E sc-221234F | 1 mg 5 mg 10 mg 50 mg 100 mg 500 mg 1 g | $75.00 $150.00 $215.00 $650.00 $1224.00 $4296.00 $7818.00 | 8 | |
ALK5 Inhibitor II (RepSox) serves as an indirect inhibitor of LRP4 through the TGF-β (Transforming Growth Factor-β) signaling pathway. By inhibiting the ALK5 receptor, RepSox attenuates TGF-β signaling, which interacts with LRP4 in neuromuscular junction regulation. | ||||||
JW 74 | 863405-60-1 | sc-507506 | 5 mg | $168.00 | ||
JW74 acts as an indirect inhibitor of LRP4 through the Wnt/β-catenin signaling pathway. By inhibiting the interaction between β-catenin and TCF (T-cell factor)/LEF (lymphoid enhancer factor) transcription factors, JW74 attenuates Wnt signaling. | ||||||
PRI-724 | 1422253-38-0 | sc-507535 | 25 mg | $255.00 | ||
PRI-724 acts as an indirect inhibitor of LRP4 through the Wnt/β-catenin signaling pathway. By inhibiting the interaction between β-catenin and CBP (CREB-binding protein), PRI-724 attenuates Wnt signaling. As LRP4 is implicated in Wnt pathway regulation, PRI-724 can potentially inhibit LRP4 activity by interfering with Wnt/β-catenin signaling. | ||||||